SPRY Insider Trading Activity and SEC Form 4 Filings
SPRY insider trading summary
Over the past 12 months, insiders at ARS Pharmaceuticals, Inc. (SPRY) reported 5 sales worth $1.9M by 4 insiders and no open-market purchases on SEC Form 4. Net insider selling was $1.9M.
Latest SPRY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Alexander A Fitzpatrick | Chief Legal Officer | Sell | $34K (3,355 @ $10.00) |
| Jun 12, 2026 | Eric Karas | Chief Commercial Officer | Sell | $250K (25,000 @ $10.00) |
| Nov 13, 2025 | Brian Dorsey | Chief Operating Officer | Sell | $190K (21,828 @ $8.71) |
| Nov 12, 2025 | Justin Chakma | Chief Business Officer | Sell | $1.2M (136,380 @ $8.86) |
| Nov 12, 2025 | Justin Chakma | Chief Business Officer | Sell | $267K (30,000 @ $8.91) |
| Aug 21, 2025 | Kathleen D. Scott | Chief Financial Officer | Sell | $188K (12,500 @ $15.00) |
| Aug 21, 2025 | Richard E Lowenthal | President and CEO | Sell | $724K (50,000 @ $14.49) |
| Aug 20, 2025 | Sarina Tanimoto | Chief Medical Officer | Sell | $531K (37,656 @ $14.09) |
| Aug 19, 2025 | Sarina Tanimoto | Chief Medical Officer | Sell | $173K (12,344 @ $14.03) |
| Jul 1, 2025 | Eric Karas | Chief Commercial Officer | Sell | $255K (15,000 @ $16.99) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.